Founded by academics and fueled by a strategic partnership with EGC, Winsantor has secured over $14.3 million in non-dilutive NIH funding since 2014, enabling breakthroughs in neuropathy treatment and advancing to Phase III clinical trials.

Client: Winsantor  .  Location: San Diego, California
Year: 2014 – Present  . Sector: BioTech  .  Link:

Founded by three faculty members from the University of Winnipeg, the University of California at San Diego, and the University of Toronto, Winsantor’s founders had extensive academic grant writing experience. However, they were unfamiliar with the SBIR/STTR program, and so in 2014, they engaged EGC to prepare an NIH SBIR Fast-Track proposal. This partnership enabled Winsantor to secure a Fast-Track award on their first attempt, providing $2.3 Million at a critical time in the company’s development. In the subsequent 10 years, Through a continued partnership with EGC, Winsantor has raised over $12 Million in funding from the NIH.

With most of its funding coming from non-dilutive sources, Winsantor has made significant progress in developing the first disease-modifying treatment for neuropathy.

In 2024, Winsantor’s CEO, Stan Kim, discussed the company’s success in securing funding at the Redefining Early Stage Investments (RESI) conference in San Francisco. Mr. Kim credited EGC with much of the company’s ability to raise funds from non-dilutive sources during a time when the company’s technology was too early to attract dilutive funding. EGC is excited to continue our partnership with Winsantor as they enter into Phase III clinical trials for their groundbreaking treatment for neuropathy.


Non-dilutive funding awarded


Years as EGC client